LHLABCORP HOLDINGS INC.
Services-Medical Laboratories
- Revenue
- $14.0B
- 7.2% YoY
- Operating margin
- 9.9%
- 19% YoY
- EBITDA
- $2.1B
- 19% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.8×
- $5.8B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear187% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear42% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear38% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $13.1B | $11.9B | $12.2B | $13.0B | $14.0B | 7.2% |
| Operating income | $3.0B | $1.4B | $726M | $1.1B | $1.4B | 27% |
| Net income | $2.4B | $1.3B | $418M | $746M | $877M | 18% |
| Operating cash flow | $3.1B | $2.0B | $1.3B | $1.6B | $1.6B | 3.4% |
| Capex | $422M | $429M | $454M | $490M | $435M | 11% |
| Stock-based comp | $133M | $117M | $129M | $117M | $126M | 7.8% |
| Buybacks | $1.7B | $1.1B | $1.0B | $250M | $450M | 80% |
| Dividends | — | $195M | $254M | $243M | $241M | 1.0% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 1
- Net
- −$2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $18M | $30M | 150 | 148 |
| FY2024 | $19M | $21M | 163 | 147 |
| FY2023 | $16M | $24M | 160 | 143 |
| FY2022 | $15M | −$2M | 140 | 140 |
| FY2021 | $21M | $50M | 186 | 143 |